{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Delaby C"],"funding":["Generalitat de Catalunya","Fondation Jérôme Lejeune","Instituto de Salud Carlos III","NIA NIH HHS","Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas","Fundació la Marató de TV3","Fundació Bancaria La Caixa","National Institute on Aging"],"pagination":["20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8809019"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["<h4>Background</h4>Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes.<h4>Aims</h4>To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression.<h4>Methods</h4>We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as \"positive\" or \"negative\" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models.<h4>Results</h4>In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78.3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73.1% and 77.1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs.<h4>Conclusion</h4>Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD."],"journal":["Alzheimer's research & therapy"],"pubmed_title":["The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone."],"pmcid":["PMC8809019"],"funding_grant_id":["PI14/01126, PI17/01019 and PI20/01473","SLT006/17/125","1R01AG056850-01A1; R21AG056974; and R01AG061566","SLT002/16/408, 2017-SGR-547","PI17/01896 and AC19/00103","20142610","20141210","044412","R21 AG056974","PI18/00335","DABNI","PI18/00435 and INT19/00016","PI13/01532 and PI16/01825","SLT006/17/119"],"pubmed_authors":["Delaby C","Subirana A","Alcolea D","Sala I","Valldeneu S","Belbin O","Videla L","Lehmann S","Altuna M","Zhu N","Blesa R","Fortea J","Estelles T","Arranz J","Barroeta I","Illan-Gala I","Tondo M","Lleo A","Carmona-Iragui M","Blanco-Vaca F","Santos-Santos MA","Sanchez-Saudinos MB"],"additional_accession":[]},"is_claimable":false,"name":"The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone.","description":"<h4>Background</h4>Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes.<h4>Aims</h4>To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression.<h4>Methods</h4>We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as \"positive\" or \"negative\" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models.<h4>Results</h4>In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78.3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73.1% and 77.1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs.<h4>Conclusion</h4>Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-05-29T16:07:02.92Z","creation":"2025-05-29T16:07:02.92Z"},"accession":"S-EPMC8809019","cross_references":{"pubmed":["35105351"],"doi":["10.1186/s13195-022-00967-z"]}}